Saturday, July 11, 2026

Drug profile · INN

valemetostat tosilate

valemetostat tosilate (EZHARMIA INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.

PMDA: approved
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — valemetostat tosilate
Class
Route
Patents
0
Programs
5
Data quality
0.78

Quick answer

valemetostat tosilate (EZHARMIA INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN valemetostat tosilate
Brand EZHARMIA INITIAL APPROVAL

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. CC-99282-NHL-001 Phase 2 · Celgene · Follicular B-cell non-Hodgkin's lymphoma, Primary central ne
  2. DS3201-330 Phase 2 · Daiichi Sankyo US · Advanced or Metastatic Non-Small Cell Lung Cancer
  3. Valemetostat Tosylate, Valemetostat Tosylate Phase 2 · George Institute for · Adult patients with histologically/cytologically confirmed p
  4. Valemetostat Tosylate, Valemetostat Tosylate Phase 2 · Daiichi Sankyo US · Relapsed/Refractory Peripheral T-Cell Lymphoma
  5. DS3201-324 Phase 1 · Daiichi Sankyo US · This study will be a Phase 1b, global, multicenter, open-lab

Frequently asked questions

What is valemetostat tosilate?

valemetostat tosilate (EZHARMIA INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for valemetostat tosilate?

EZHARMIA INITIAL APPROVAL is a marketed brand name for valemetostat tosilate. Check FDA Drugs@FDA for the current US label holder and prescribing information.